|Bid||0.9200 x 800|
|Ask||1.1500 x 2200|
|Day's Range||0.9201 - 1.0110|
|52 Week Range||0.4700 - 3.3000|
|Beta (3Y Monthly)||0.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
WARREN, N.J., Oct. 09, 2018 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided an.
GTBiopharma (GTBP), for instance has been building a biopharmaceutical pipeline targeting everything from pain management to cancer treatments. This therapy targets cancer cells expressing the CD19 receptor and/or CD22 receptors, which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploys its cytotoxic diphtheria toxin payload, which inhibits protein synthesis and kills the cancer cells.
WARREN, N.J., Aug. 29, 2018-- Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, Chief Executive Officer, will provide a corporate overview ...
NEW YORK, NY / ACCESSWIRE / August 20, 2018 / Tesla shares were hammered on Friday after CEO Elon Musk revealed to the New York Times that the stress of his job is getting to him. Shares of Bellerophon Therapeutics saw unusual activity, climbing over 20% despite any news. Tesla, Inc. shares plummeted nearly 9% on Friday.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on Aug. 7) Akcea Therapeutics Inc (NASDAQ: AKCA )(reacted to Q2 earnings ...
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 75 enrolled subjects completing 16-weeks of treatment in the Phase 3 INOvation-1 study evaluating INOpulse® for the treatment of pulmonary arterial hypertension (PAH). As previously agreed upon with the U.S. Food and Drug Administration (FDA), the pre-specified interim analysis was conducted by the DMC after half of the planned subjects completed 16-weeks of blinded treatment. The DMC considered four potential recommendations relative to its review of the data: stopping the trial early for efficacy, continuing to enroll the study as planned, increasing the targeted enrollment size if the original design was slightly underpowered, and stopping the study for futility or safety concerns.
The Warren, New Jersey-based company said it had a loss of 20 cents per share. The company's shares closed at $2.50. A year ago, they were trading at $1.30. _____ This story was generated by Automated ...
WARREN, N.J., Aug. 01, 2018-- Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the second quarter ended June ...
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp
In the latest edition of the drama on trade and tariffs, President Trump upped the ante against traditional U.S. allies on Monday. In a series of tweets, he attacked Canada and European trading partners, accusing them of heavy tariffs on U.S. products. Additionally, these are likely to benefit the most from the Trump administration’s tax cuts.
The U.S. stock market is facing a severe volatility since the last couple of months despite a strong start this year. This downside can mainly be attributable to a potentially damaging trade war between the world’s two largest economies, United States and China, since this February.Source: Shutterstock
Stock Monitor: Bellerophon Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on Intercept Pharma, Inc. (NASDAQ: ...
The Warren, New Jersey-based company said it had a loss of 44 cents per share. Losses, adjusted for non-recurring costs, came to 24 cents per share. For the year, the company reported that its loss widened ...